LU92602I2 - Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci - Google Patents

Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci Download PDF

Info

Publication number
LU92602I2
LU92602I2 LU92602C LU92602C LU92602I2 LU 92602 I2 LU92602 I2 LU 92602I2 LU 92602 C LU92602 C LU 92602C LU 92602 C LU92602 C LU 92602C LU 92602 I2 LU92602 I2 LU 92602I2
Authority
LU
Luxembourg
Prior art keywords
agent
pharmaceutically acceptable
acceptable salt
antitumor
trametinib
Prior art date
Application number
LU92602C
Other languages
English (en)
French (fr)
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of LU92602I2 publication Critical patent/LU92602I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
LU92602C 2004-06-11 2014-11-19 Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci LU92602I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004174770 2004-06-11
JP2004327111 2004-11-10
PCT/JP2005/011082 WO2005121142A1 (en) 2004-06-11 2005-06-10 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
LU92602I2 true LU92602I2 (fr) 2015-10-27

Family

ID=34970318

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92602C LU92602I2 (fr) 2004-06-11 2014-11-19 Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci

Country Status (27)

Country Link
EP (3) EP1761528B1 (pt)
JP (3) JP4163738B2 (pt)
KR (1) KR100883289B1 (pt)
CN (2) CN101912400B (pt)
AT (1) ATE383360T1 (pt)
AU (1) AU2005252110B2 (pt)
BR (1) BRPI0511967B8 (pt)
CA (2) CA2569850C (pt)
CY (3) CY1107253T1 (pt)
DE (1) DE602005004286T2 (pt)
DK (2) DK1761528T3 (pt)
ES (2) ES2397825T3 (pt)
HK (1) HK1107084A1 (pt)
HR (2) HRP20080018T3 (pt)
IL (1) IL179671A0 (pt)
LU (1) LU92602I2 (pt)
ME (1) ME01480B (pt)
MX (1) MXPA06014478A (pt)
NL (1) NL300701I2 (pt)
NO (2) NO338355B1 (pt)
NZ (1) NZ552090A (pt)
PL (2) PL1761528T3 (pt)
PT (2) PT1761528E (pt)
RS (2) RS50569B (pt)
RU (1) RU2364596C2 (pt)
SI (2) SI2298768T1 (pt)
WO (1) WO2005121142A1 (pt)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1912636T3 (pl) 2005-07-21 2015-02-27 Ardea Biosciences Inc N-(aryloamino)sulfonamidowe inhibitory mek
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
US8063066B2 (en) 2007-03-19 2011-11-22 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
EP2172198B1 (en) * 2007-07-20 2014-04-16 Chugai Seiyaku Kabushiki Kaisha p27 PROTEIN INDUCER
ES2456966T3 (es) * 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CA2742945A1 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
EP2362775B1 (en) 2008-11-20 2015-08-05 GlaxoSmithKline LLC Chemical compounds
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
CN102361557A (zh) * 2009-03-26 2012-02-22 Mapi医药公司 制备阿格列汀的方法
CN101619063B (zh) * 2009-06-02 2011-08-10 华中师范大学 具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备
WO2011031308A1 (en) * 2009-09-09 2011-03-17 Cytokinetics, Incorporated Novel combinations
EP2480085B1 (en) * 2009-09-23 2014-11-12 GlaxoSmithKline LLC Combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide and the Akt inhibitor N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1- methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide
KR20120099219A (ko) * 2009-09-23 2012-09-07 글락소스미스클라인 엘엘씨 조합물
JP2013505962A (ja) * 2009-09-28 2013-02-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
MX2012004139A (es) * 2009-10-08 2012-09-07 Glaxosmithkline Llc Combinacion.
DK3560498T3 (da) 2009-10-16 2022-11-14 Novartis Ag Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
CN102574782B (zh) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
CN104382906A (zh) * 2009-11-17 2015-03-04 葛兰素史密斯克莱有限责任公司 药物组合
RU2571930C2 (ru) 2010-02-25 2015-12-27 Дана-Фарбер Кэнсер Инститьют, Инк. Мутации braf, обеспечивающие резистентность к ингибиторам braf
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
EP2558092B1 (en) * 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
JP5858989B2 (ja) 2010-05-21 2016-02-10 ノバルティス アーゲー 組合せ
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
EP2608790A4 (en) * 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
US9045429B2 (en) 2010-10-29 2015-06-02 Bayer Intellectual Property Gmbh Substituted phenoxypyridines
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
US20130217710A1 (en) * 2010-11-05 2013-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cancer
US20130231346A1 (en) * 2010-11-17 2013-09-05 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
JP2013543008A (ja) * 2010-11-19 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド Ｂｒａｆ阻害剤による治療方法
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
ES2603479T3 (es) 2010-12-20 2017-02-27 Novartis Ag Terapia de combinación que comprende gemcitabina para el tratamiento de cáncer pancreático
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2013019620A2 (en) * 2011-07-29 2013-02-07 Glaxosmithkline Llc Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
KR102049817B1 (ko) 2011-08-01 2019-12-02 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
BR112014004587A2 (pt) 2011-08-31 2017-03-14 Novartis Ag combinações sinérgicas de inibidores de pi3k- e de mek
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии
JP6431770B2 (ja) 2012-03-14 2018-11-28 ルピン・リミテッド Ｍｅｋインヒビターとしてのヘテロシクリル化合物
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
IN2015KN00449A (pt) * 2012-09-04 2015-07-17 Glaxosmithkline Llc
CA2889530A1 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
HUE037618T2 (hu) 2012-11-29 2018-09-28 Novartis Ag Gyógyszerészeti kombinációk
AU2013352369B2 (en) 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
CA2897559A1 (en) 2013-01-09 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Combination
JP6465790B2 (ja) 2013-02-27 2019-02-06 第一三共株式会社 Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
TW201536292A (zh) 2013-05-28 2015-10-01 Glaxosmithkline Ip No 2 Ltd 癌症治療方法
WO2014195852A1 (en) 2013-06-03 2014-12-11 Glaxosmithkline Intellectual Property (No.2) Limited Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
MX2016004742A (es) * 2013-10-25 2016-12-09 Shanghai hengrui pharmaceutical co ltd Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos.
WO2015059677A1 (en) 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
KR20160088884A (ko) 2013-12-12 2016-07-26 노파르티스 아게 암의 치료를 위한 트라메티닙, 파니투무맙 및 다브라페닙의 조합물
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
SG10202007111TA (en) 2014-07-15 2020-09-29 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016009306A1 (en) 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
EP3200775B1 (en) 2014-10-03 2019-11-20 Novartis AG Combination therapies
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017037574A1 (en) 2015-08-28 2017-03-09 Novartis Ag Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
US20190060309A1 (en) 2015-08-28 2019-02-28 Novartis Ag Mdm2 inhibitors and combinations thereof
AU2016348391A1 (en) 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
RU2605400C1 (ru) * 2015-11-13 2016-12-20 ЗАО "Р-Фарм" ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR TREATING MALIGNANT TUMORS
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
CN107970246B (zh) * 2016-10-21 2020-08-28 中山大学 非甾体类抗炎药在提高肿瘤细胞对酪氨酸激酶抑制剂的敏感性中的应用
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
KR102114017B1 (ko) 2016-11-25 2020-05-22 주식회사 지뉴브 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법
JP2020510618A (ja) 2016-12-01 2020-04-09 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌を処置する方法
FI3618875T3 (fi) 2017-05-02 2023-07-04 Novartis Ag Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
WO2019181876A1 (ja) 2018-03-19 2019-09-26 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
BR112020019577A2 (pt) 2018-03-30 2021-01-05 Novartis Ag Combinação farmacêutica tripla compreendendo dabrafenibe, trametinibe e um inibidor de erk
EP3560516A1 (en) 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
EP3802609A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Psma binding agents and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3867409A1 (en) 2018-10-16 2021-08-25 Novartis AG Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
CN109320513B (zh) * 2018-11-09 2021-03-16 安庆奇创药业有限公司 一种合成曲美替尼的方法
CA3120371A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020106308A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
BR112021010353A2 (pt) 2018-11-30 2021-08-31 Glaxosmithkline Intellectual Property Development Limited Compostos úteis em terapia hiv
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020161654A1 (en) * 2019-02-06 2020-08-13 Aurobindo Pharma Limited A process for the preparation of trametinib acetic acid solvate
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
KR20220002899A (ko) 2019-04-19 2022-01-07 얀센 바이오테크 인코포레이티드 항-psma/cd3 항체로 전립선암을 치료하는 방법
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202114994A (zh) * 2019-07-29 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種１，６－二氫吡啶－３－甲醯胺衍生物的製備方法
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
EP4087868A4 (en) * 2020-01-08 2024-03-20 Icahn School Med Mount Sinai SMALL MOLECULAR MODULATORS FOR KSR-BONDED MEK
US20230226030A1 (en) 2020-02-18 2023-07-20 Novartis Ag Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
TW202200146A (zh) 2020-04-10 2022-01-01 日商大鵬藥品工業股份有限公司 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021229439A1 (en) 2020-05-12 2021-11-18 Novartis Ag Therapeutic combinations comprising a craf inhibitor
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
TW202227088A (zh) 2020-08-31 2022-07-16 瑞士商諾華公司 組合療法
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20230131189A (ko) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2022159986A1 (en) 2021-01-25 2022-07-28 Ikena Oncology, Inc. Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
WO2022162518A2 (en) 2021-01-28 2022-08-04 Janssen Biotech, Inc. Psma binding proteins and uses thereof
CA3206906A1 (en) 2021-02-02 2022-08-11 Andras Herner Selective bcl-xl protac compounds and methods of use
JP2024511373A (ja) 2021-03-18 2024-03-13 ノバルティス アーゲー がんのためのバイオマーカーおよびその使用
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4319757A1 (en) 2021-04-09 2024-02-14 Boehringer Ingelheim International GmbH Anticancer therapy
KR20230172548A (ko) * 2021-04-16 2023-12-22 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
CN117177752A (zh) 2021-05-05 2023-12-05 诺华股份有限公司 用于治疗mpnst的化合物和组合物
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023166345A2 (en) 2022-03-02 2023-09-07 Novartis Ag Precision therapy for the treatment of cancer
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN114853754B (zh) * 2022-05-23 2023-04-18 云白药征武科技(上海)有限公司 一种硫代酰胺衍生物及其制备方法和应用
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
WO2023230541A1 (en) 2022-05-27 2023-11-30 Viiv Healthcare Company Piperazine derivatives useful in hiv therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3139432A (en) * 1963-06-24 1964-06-30 Mead Johnson & Co Pyrido [2, 3-d] pyrimidine-2, 4, 5, 7-tetraones
DE4035479A1 (de) * 1990-11-08 1992-05-14 Basf Ag Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione
TR200101704T2 (tr) 1998-12-15 2001-11-21 Warner-Lambert Company Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
US6696440B1 (en) 1999-01-07 2004-02-24 Warner-Lambert Company Treatment of asthma with MEK inhibitors
WO2000040237A1 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
IL147618A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
AU2001271067A1 (en) 2000-07-19 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Method of screening compound controlling mek/erk signal transduction and medicinal use of the compound
US6960614B2 (en) 2000-07-19 2005-11-01 Warner-Lambert Company Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
EP1391211A1 (en) 2001-04-27 2004-02-25 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES

Also Published As

Publication number Publication date
CN101006086A (zh) 2007-07-25
ME01480B (me) 2014-04-20
CY2014045I1 (el) 2019-07-10
PT2298768E (pt) 2012-12-05
IL179671A0 (en) 2007-05-15
CN101912400B (zh) 2013-06-26
CY1113538T1 (el) 2016-06-22
RU2007101158A (ru) 2008-07-20
AU2005252110A1 (en) 2005-12-22
EP2298768B9 (en) 2013-04-24
JP5421974B2 (ja) 2014-02-19
BRPI0511967B8 (pt) 2021-05-25
DK2298768T3 (da) 2013-01-02
CY1107253T1 (el) 2012-11-21
EP2298768B1 (en) 2012-11-14
NZ552090A (en) 2009-06-26
NO338355B1 (no) 2016-08-08
CA2727841A1 (en) 2005-12-22
WO2005121142A1 (en) 2005-12-22
MXPA06014478A (es) 2007-03-21
RS50569B (sr) 2010-05-07
PL1761528T3 (pl) 2008-05-30
RU2364596C2 (ru) 2009-08-20
PT1761528E (pt) 2008-04-15
KR100883289B1 (ko) 2009-02-11
EP2298768A1 (en) 2011-03-23
SI1761528T1 (sl) 2008-06-30
HRP20080018T3 (en) 2008-01-31
CN101006086B (zh) 2010-09-29
JP4163738B2 (ja) 2008-10-08
NO20070155L (no) 2007-02-13
NL300701I1 (pt) 2015-12-29
PL2298768T3 (pl) 2013-03-29
EP1761528A1 (en) 2007-03-14
SI2298768T1 (en) 2013-01-31
RS52670B (en) 2013-06-28
NL300701I2 (pt) 2015-12-29
JP2008201788A (ja) 2008-09-04
ATE383360T1 (de) 2008-01-15
EP1894932A1 (en) 2008-03-05
BRPI0511967A (pt) 2008-01-22
JP4913768B2 (ja) 2012-04-11
HK1107084A1 (en) 2008-03-28
CA2569850A1 (en) 2005-12-22
EP1761528B1 (en) 2008-01-09
ES2297723T3 (es) 2008-05-01
KR20070034581A (ko) 2007-03-28
DE602005004286D1 (de) 2008-02-21
CA2569850C (en) 2011-04-05
ES2397825T3 (es) 2013-03-11
NO2016021I1 (no) 2016-11-24
NO2016021I2 (no) 2016-11-24
CN101912400A (zh) 2010-12-15
AU2005252110B2 (en) 2008-09-04
DK1761528T3 (da) 2008-05-05
HRP20121020T1 (hr) 2013-01-31
JP2012072155A (ja) 2012-04-12
DE602005004286T2 (de) 2009-01-02
JP2008501631A (ja) 2008-01-24
CY2014045I2 (el) 2019-07-10
BRPI0511967B1 (pt) 2019-05-07

Similar Documents

Publication Publication Date Title
LU92602I2 (fr) Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
SG166827A1 (en) Aminopyrimidines useful as kinase inhibitors
LU92155I2 (fr) Crizotinib, éventuellement sous la forme d'un sel,hydrate ou solvate pharmeceutiquement acceptable
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
MX2009006700A (es) Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
TW200616976A (en) Pyrimidine derivatives
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MX2007013624A (es) Inhibidores de proteina cinasa.
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
DE602004011394D1 (en) Thiazolderivate
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
MY154591A (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TNSN08093A1 (en) Quinoline derivatives and use as antitumor agents